FibroGen, Inc. (NASDAQ:FGEN) Short Interest Down 15.2% in July

FibroGen, Inc. (NASDAQ:FGEN) was the target of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 5,040,000 shares, a decline of 15.2% from the July 15th total of 5,940,000 shares. Based on an average trading volume of 2,620,000 shares, the days-to-cover ratio is currently 1.9 days.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on FGEN. StockNews.com began coverage on shares of FibroGen in a report on Sunday. They set a “hold” rating for the company. William Blair reissued a “market perform” rating on shares of FibroGen in a report on Monday, June 3rd.

Insider Activity

In other FibroGen news, insider Deyaa Adib acquired 22,123 shares of the stock in a transaction on Wednesday, June 12th. The shares were bought at an average cost of $1.17 per share, with a total value of $25,883.91. Following the transaction, the insider now owns 82,123 shares of the company’s stock, valued at approximately $96,083.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.98% of the company’s stock.

Hedge Funds Weigh In On FibroGen

Hedge funds have recently bought and sold shares of the company. Armistice Capital LLC lifted its holdings in shares of FibroGen by 23.7% in the fourth quarter. Armistice Capital LLC now owns 9,764,000 shares of the biopharmaceutical company’s stock valued at $8,654,000 after purchasing an additional 1,872,000 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of FibroGen by 34.4% during the 2nd quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock worth $2,997,000 after purchasing an additional 860,854 shares during the last quarter. AQR Capital Management LLC lifted its stake in FibroGen by 139.6% in the 2nd quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock valued at $1,179,000 after buying an additional 769,586 shares in the last quarter. Pennant Investors LP acquired a new stake in FibroGen during the 4th quarter valued at $681,000. Finally, XTX Topco Ltd purchased a new position in FibroGen during the second quarter worth $424,000. 72.71% of the stock is owned by hedge funds and other institutional investors.

FibroGen Stock Performance

Shares of NASDAQ FGEN remained flat at $0.37 during trading on Friday. 1,363,820 shares of the company’s stock traded hands, compared to its average volume of 2,635,493. FibroGen has a 52 week low of $0.33 and a 52 week high of $2.93. The stock has a market cap of $36.36 million, a P/E ratio of -0.15 and a beta of 0.71. The stock has a 50-day moving average price of $0.88 and a two-hundred day moving average price of $1.39.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09. The company had revenue of $50.64 million for the quarter, compared to analysts’ expectations of $33.00 million. During the same period in the prior year, the firm posted ($0.65) EPS. As a group, sell-side analysts forecast that FibroGen will post -1.05 earnings per share for the current year.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.